BioSpace News Archive

VICHY Laboratoires announced today a partnership with Embr Labs, a leading health-tech company addressing hot flashes and sleep to help women thrive in peri- and post-menopause.

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their first-in-class CNS-102 feasibility study at the European Network to Cure ALS Annual Meeting (ENCALS) in Barcelona, Spain.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2023 and reiterated full-year guidance.

Transcat, Inc., a leading provider of accredited calibration services, enterprise asset management services, and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it has purchased all of the capital stock of privately-held SteriQual, Inc., effective July 12, 2023.

Current Surgical Inc. today announced that it has received a $400,000 grant from the National Institutes of Health (NIH) to support the development of its technology.

60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its initial public offering of 1,415,095 units (each, a “Unit,” collectively, the “Units”) at a price of $5.30 per Unit for a total of approximately $7.5 million of gross proceeds to the Company.

Velico Medical has begun a Phase I safety study for their FrontlineODP (OnDemandPlasma) Spray Dried Plasma product in a multi-center, dose escalation clinical trial.

Bicycle Therapeutics plc announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023.

89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,600 shares of the Company’s common stock to one new employee on the later of July 6, 2023 and the employee’s commencement of employment with the Company.